Trump Administration Strikes Medicaid Drug-Price Deals With Biotechs, Tying Rates to Foreign Markets
Updated
Updated · STAT · Aug 27
Trump Administration Strikes Medicaid Drug-Price Deals With Biotechs, Tying Rates to Foreign Markets
3 articles · Updated · STAT · Aug 27
Summary
Monday’s planned agreements would have several midsized biotech companies offer state Medicaid programs discounts on outpatient drugs so prices match what the companies charge abroad.
State participation would be optional, but the companies would gain an exemption from Medicare pilot programs designed to force similar international-reference discounts.
Tariff relief is also part of some talks, broadening the package beyond drug pricing as the administration tries to secure industry buy-in.
The deals would mark a targeted pricing push focused on midsized biotechs and Medicaid rather than a blanket federal mandate across the drug market.
Will new Medicaid pricing rules crush the midsized innovators behind this formerly undruggable cancer breakthrough?
Could this unprecedented survival rate finally signal the end of chemotherapy as the default for deadly cancers?
What hidden genetic resistance mechanisms could eventually outsmart this revolutionary new pancreatic cancer treatment?
U.S. Drug Prices in 2026: The TrumpRx Rollout, MFN Deals, and the Battle Over Affordable Medicines
Overview
The Trump administration’s TrumpRx platform rapidly expanded in 2026, integrating Mark Cuban’s Cost Plus Drugs and offering discounts on over 800 medications. While the program claims over $400 million in patient savings, most insured Americans still pay less through traditional co-pays, and TrumpRx’s prices largely mirror those on GoodRx. The administration’s aggressive use of tariff threats pushed pharmaceutical companies to negotiate, but the resulting Most Favored Nation (MFN) deals remain confidential and complex. These policies have led drugmakers to delay or withdraw products from lower-priced markets to protect U.S. revenues, raising concerns about global drug access and the future of pharmaceutical innovation.